INTRODUCTION. Glioblastoma (GBM) is the most common and aggressive malignant brain tumor in adults. The current therapeutic approach is based on surgical resection, where feasible, followed by radiotherapy combined with temozolomide (TMZ) chemotherapy, an alkylating agent acting at the genomic level. However, despite this multimodal approach, the prognosis remains poor, due to high recurrence rate and the development of radioresistance. To address this issue, combinatorial pharmacological strategies exploiting the inhibition of specific molecular targets have been tested to sensitize GBM cells to radiotherapy. MATERIALS AND METHODS. The basal expression of targeted molecular candidates was measured across 4 different cell lines, both at the transcriptional level via quantitative Real-Time PCR, and at the protein level via western blot and CBD450 cell barcoding. These cell lines were also compared to evaluate potential metabolic differences through the extracellular flux analysis by Seahorse assay (XF Analyzer), assessing the oxygen consumption rate (OCR) and extracellular acidification rate (ECAR). The LN229 cell line was selected as the reference for subsequent experiments, as it expresses both target proteins of the investigated drugs and exhibits higher glycolytic activity. Cells were treated in vitro with single drugs or drug combinations, with or without radiotherapy. Flow cytometry was used to analyze: (i) the cytotoxic effect induced by the treatments, detecting cell death and changes in mitochondrial and cytosolic reactive oxygen species (ROS) levels; and (ii) cell cycle arrest in the G2 phase. RESULTS. Expression analysis of the pharmacological targets revealed heterogeneity among the different cell lines, and the Seahorse assay highlighted distinct metabolic profiles. Combined treatment with drugs and radiotherapy in the LN229 line induced an increase in mitochondrial ROS levels and cell cycle arrest. CONCLUSION. These results demonstrate that the synergistic inhibition of specific molecular targets represents a promising strategy for overcoming radioresistence in GBM. Further studies are required to validate the efficacy of this combination ex vivo and to elucidate the underlying molecular mechanisms in detail.
INTRODUZIONE. Il glioblastoma (GBM) è il tumore cerebrale maligno più comune ed aggressivo nell’adulto. L’attuale approccio terapeutico si basa sulla resezione chirurgica, ove possibile, seguita da radioterapia associata a chemioterapia con temozolomide (TMZ), un agente alchilante che agisce a livello genomico. Tuttavia, malgrado questo approccio multiplo, la prognosi rimane infausta a causa dell’elevato tasso di recidiva e dello sviluppo di radioresistenza. Per far fronte al problema, sono state testate strategie farmacologiche combinatorie che sfruttino l’inibizione di specifici bersagli molecolari per sensibilizzare le cellule di GBM alla radioterapia. MATERIALI E METODI. L’espressione basale di bersagli molecolari d’interesse è stata misurata in 4 diverse linee cellulari di GBM a livello trascrizionale tramite Real Time PCR quantitativa, e a livello proteico tramite western blot e barcoding con CBD450. Le medesime linee cellulari sono state, inoltre, confrontate per verificare eventuali differenze a livello metabolico mediante analisi del flusso extracellulare(Seahorse XF Analyzer), valutando il tasso di consumo di ossigeno (OCR) e di acidificazione extracellulare (ECAR). La linea LN229 è stata selezionata come riferimento per gli esperimenti successivi in quanto caratterizzata dalla presenza di entrambe le proteine bersaglio dei farmaci in studio e da una maggior attività glicolitica. Le cellule sono state trattate in vitro con singoli farmaci o combinazioni di essi associati o meno a radioterapia. Tramite citofluorimetria sono stati analizzati: (i) l’effetto citotossico indotto dai trattamenti, rilevando eventuali morte cellulare e variazioni dei livelli di specie reattive dell’ossigeno (ROS) mitocondriali e citosolici; (ii) la distribuzione del ciclo cellulare. RISULTATI. L’analisi dell’espressione dei target farmacologici ha evidenziato un’eterogeneità tra le diverse linee cellulari e, tramite saggio Seahorse, è stato possibile osservare differenze a livello metabolico. Il trattamento combinato tra farmaci e radioterapia nella linea LN229 mostra un incremento dei livelli di ROS mitocondriali e un arresto del ciclo cellulare in fase G2. CONCLUSIONE. I risultati ottenuti dimostrano come nel GBM l’inibizione sinergica di specifici target molecolari rappresenti un’opzione promettente per il superamento della radioresistenza. Ulteriori studi devono essere condotti al fine di validare l’efficacia di questa combinazione ex vivo e chiarirne nei dettagli i meccanismi molecolari sottostanti.
Sviluppo di strategie farmacologiche combinatorie per il superamento della resistenza alla radioterapia nel glioblastoma
PREDONZAN, SABRINA
2025/2026
Abstract
INTRODUCTION. Glioblastoma (GBM) is the most common and aggressive malignant brain tumor in adults. The current therapeutic approach is based on surgical resection, where feasible, followed by radiotherapy combined with temozolomide (TMZ) chemotherapy, an alkylating agent acting at the genomic level. However, despite this multimodal approach, the prognosis remains poor, due to high recurrence rate and the development of radioresistance. To address this issue, combinatorial pharmacological strategies exploiting the inhibition of specific molecular targets have been tested to sensitize GBM cells to radiotherapy. MATERIALS AND METHODS. The basal expression of targeted molecular candidates was measured across 4 different cell lines, both at the transcriptional level via quantitative Real-Time PCR, and at the protein level via western blot and CBD450 cell barcoding. These cell lines were also compared to evaluate potential metabolic differences through the extracellular flux analysis by Seahorse assay (XF Analyzer), assessing the oxygen consumption rate (OCR) and extracellular acidification rate (ECAR). The LN229 cell line was selected as the reference for subsequent experiments, as it expresses both target proteins of the investigated drugs and exhibits higher glycolytic activity. Cells were treated in vitro with single drugs or drug combinations, with or without radiotherapy. Flow cytometry was used to analyze: (i) the cytotoxic effect induced by the treatments, detecting cell death and changes in mitochondrial and cytosolic reactive oxygen species (ROS) levels; and (ii) cell cycle arrest in the G2 phase. RESULTS. Expression analysis of the pharmacological targets revealed heterogeneity among the different cell lines, and the Seahorse assay highlighted distinct metabolic profiles. Combined treatment with drugs and radiotherapy in the LN229 line induced an increase in mitochondrial ROS levels and cell cycle arrest. CONCLUSION. These results demonstrate that the synergistic inhibition of specific molecular targets represents a promising strategy for overcoming radioresistence in GBM. Further studies are required to validate the efficacy of this combination ex vivo and to elucidate the underlying molecular mechanisms in detail.| File | Dimensione | Formato | |
|---|---|---|---|
|
Sabrina Predonzan_2117807.pdfA.pdf
Accesso riservato
Dimensione
4.89 MB
Formato
Adobe PDF
|
4.89 MB | Adobe PDF |
The text of this website © Università degli studi di Padova. Full Text are published under a non-exclusive license. Metadata are under a CC0 License
https://hdl.handle.net/20.500.12608/119269